2025 Multiple Myeloma March (MMM) Research Fund-Sharing Partnership Program

The Multiple Myeloma March Research Fund-Sharing Partnership Program allows charitable organizations to partner with Myeloma Canada on their nearest MMM and be awarded a research grant of up to 50% of net proceeds!

Participants of the 2025 MMM Research Fund-Sharing Partnership Program

Hamilton-Niagara Multiple Myeloma March

In 2025, Myeloma Canada is proudly partnering with McMaster University to raise funds for a local research project led by Dr. Jonathan Bramson.

The project, entitled “Interrogating the Spatial Biology of Multiple Myeloma,” will use cutting‑edge imaging technology to create detailed maps of how myeloma cells and nearby immune cells interact inside the bone marrow.

By visualizing these cell‑to‑cell “conversations,” Dr. Bramson and his team at the  aim to uncover new treatment targets and accelerate the development of personalized, more effective therapies for multiple myeloma.

Quebec City Multiple Myeloma March

In 2025, Myeloma Canada is once again proudly partnering with CHU de Québec to raise funds for a local research project led by Dr Julie Côté.

The project, entitled “Immunoglobulins in Multiple Myeloma Patients Receiving a BCMA-Directed T Cell Engager”, will help clinicians better define the use of immunoglobulin (IgG) replacement in myeloma. BCMA‑directed T cell engagers can drive IgG levels dangerously low, putting patients at high risk for serious infections. Clinicians use IgG replacement therapy to restore immunity, but the optimal IgG target level remains unknown.

Dr Côté’s study will compare two different IgG target levels, assess their impact on infection rates and quality of life, and deliver clear, evidence‑based guidelines on when and how to use IgG replacement in myeloma care.